<DOC>
	<DOCNO>NCT01661244</DOCNO>
	<brief_summary>RV568 develop possible treatment smoking relate lung disease ( also know Chronic Obstructive Pulmonary Disease - COPD ) . The main purpose study examine safety tolerability new inhaled formulation RV568 healthy volunteer . The study run two part ; Part A Part B . Part A ( Cohorts 1 , 2 &amp; 3 ) investigate 6 different dose level RV568 give single dose Part B ( Cohorts 4 &amp; 5 ) investigate 2 different dose level RV568 give day 14 day .</brief_summary>
	<brief_title>A Study Investigate Safety Tolerability New Inhaled Formulation RV568 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . Healthy determine physician , base full medical evaluation include medical history , physical examination , laboratory test . Body weight ≥50 kg body mass index within range 1929 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Average QTc ( B ) QTc ( F ) &lt; 450 msec ( QTc &lt; 480 msec healthy subject right bundle branch block ) . Capable comply study restriction procedure include ability use Dry Powder Inhaler correctly . Spirometry reading ( FEV1 FVC ) ≥ 80 % predict value FEV1/FVC ratio &gt; 0.7 calculate use ECCS reference equation . Vital sign assessment within normal range ( systolic blood pressure ( SBP ) 90 140 mm/Hg ; diastolic blood pressure ( DBP ) 55 90 mm/Hg ; heart rate ( HR ) 40 100 bpm ) . Agree use prescription medication within 14 day first administration study medication duration study ( exception contraception hormone replacement therapy ( HRT ) ) . Agree use counter ( OTC ) medication ( include corticosteroid , decongestant , antihistamine , aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) ) herbal medication ( include , limited , herbal tea St. John 's Wort ) , within 14 day first administration study medication final follow visit , unless approve Investigator Sponsor Medical Monitor . Occasional use paracetamol recommend dos ( ≤ 1 g/ 6 hour ≤ 2 g/day ) continue preexist use vitamin recommend dos allow . Any acute chronic illness clinically relevant abnormality identify screen medical assessment , laboratory test ECG . Upper low respiratory tract infection within 4 week screen visit . A positive prestudy hepatitis B surface antigen positive hepatitis C antibody result screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Positive urinary drug breath alcohol test screen prior dosing . The Investigator suspect drug alcohol abuse . A positive test human immunodeficiency virus antibody . History regular alcohol consumption within 6 month study . The subject participate study investigational drug 3 month receipt first dose study medication previously receive RV568 . Regular use prescription nonprescription drug within 14 day prior first dose study medication . Allergy active inactive ingredient study medication . History drug , allergy , opinion Investigator Sponsor Medical Monitor , would contraindicate participation . The subject smoker ( regular irregular ) , smoke use nicotinecontaining product within 6 month prior screen . Positive carbon monoxide breath test screen visit indicative smoking use tobacco nicotinecontaining product . Donation blood excess 500 mL within 3 month period prior screening , study participation would result blood loss excess 500 mL 3 month period . The subject unable unwilling comply fully study protocol . Subject mentally legally incapacitate . Subject employee Sponsor contract research organization ( CRO ) , relative employee Sponsor CRO . Unable unwilling undergo multiple venepuncture procedure subject poor access vein suitable cannulation . A positive pregnancy test lactating ( nurse ) female . Any reason Investigator considers make subject unsuitable participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>